Evidence map›Paper›PMID 27928004›Full record

ArticleJournal of virology2017

Effect of HIV-1 Env on SERINC5 Antagonism.

Saina Beitari, Shilei Ding, Qinghua Pan, Andrés Finzi, Chen Liang

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Saina BeitariLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
Shilei DingCentre de Recherche du CHUM Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Quebec, Canada.
Qinghua PanLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
Andrés FinziDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
Chen LiangLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada chen.liang@mcgill.ca.
Jewish General Hospital · CAMcGill University · CACentre Hospitalier de l’Université de Montréal · CA

Funding

CIHR
6 · The paper itself

Abstract

SERINC5 is able to restrict HIV-1 infection by drastically impairing the infectivity of viral particles. Studies have shown that the HIV-1 Nef protein counters SERINC5 through downregulating SERINC5 from the cell surface and preventing the virion incorporation of SERINC5. In addition, the Env proteins of some HIV-1 strains can also overcome SERINC5 inhibition. However, it is unclear how HIV-1 Env does so and why HIV-1 has two mechanisms to resist SERINC5 inhibition. The results of this study show that neither Env nor Nef prevents high levels of ectopic SERINC5 from being incorporated into HIV-1 particles, except that Env, but not Nef, is able to resist inhibition by virion-associated SERINC5. Testing of a panel of HIV-1 Env proteins from different subtypes revealed a high frequency of SERINC5-resistant Envs. Interestingly, although the SERINC5-bearing viruses were not inhibited by SERINC5 itself, they became more sensitive to the CCR5 inhibitor maraviroc and some neutralizing antibodies than the SERINC5-free viruses, which suggests a possible influence of SERINC5 on Env function. We conclude that HIV-1 Env is able to overcome SERINC5 without preventing SERINC5 virion incorporation. IMPORTANCE: HIV-1 Nef is known to enhance the infectivity of HIV-1 particles and to contribute to the maintenance of high viral loads in patients. However, the underlying molecular mechanism remained elusive until the recent discovery of the antiviral activity of SERINC5. SERINC5 profoundly inhibits HIV-1 but is antagonized by Nef, which prevents the incorporation of SERINC5 into viral particles. Here, we show that HIV-1 Env, but not Nef, is able to resist high levels of SERINC5 without excluding SERINC5 from incorporation into viral particles. However, the virion-associated SERINC5 renders HIV-1 more sensitive to some broadly neutralizing antibodies. It is possible that, under the pressure of some neutralizing antibodies in vivo, HIV-1 needs Nef to remove SERINC5 from viral particles, even though viral Env is able to resist virion-associated SERINC5.

Indexed as

Amino Acid SequenceAntibodies, NeutralizingCell LineCells, Culturedenv Gene Products, Human Immunodeficiency VirusHIV-1HIV Envelope Protein gp120HIV InfectionsHost-Pathogen InteractionsHumansInhibitory Concentration 50Membrane GlycoproteinsMembrane Proteinsnef Gene Products, Human Immunodeficiency VirusPeptide FragmentsViral Envelope ProteinsAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusG protein, vesicular stomatitis virusHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)Membrane GlycoproteinsMembrane Proteinsnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1Peptide FragmentsSERINC5 protein, humanViral Envelope ProteinsEnvhuman immunodeficiency virusNefSERINC5

Identifiers

PMID27928004
PMCPMC5286904
OpenAlexW2559983804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.